arrow_backToday
Archive
Neurology — 414 items, newest first. Nothing is deleted.
Friday, 11 September 2026
Systematic Review and Meta-Analysis on Central and/or Peripheral Nervous System Demyelination in Patients Treated With Tumor Necrosis Factor Alpha (TNF-α) Inhibitors
Pooled random-effects estimates: RR 1.46 (95% CI 1.09-1.95) for CNS demyelination and RR 2.00 (95% CI 1.19-3.38) for PNS demyelination.
Neurology · Cureus · 14h
Cardiac Metastasis From Lung Cancer: A Hidden Cardioembolic Source of Acute Ischemic Stroke
Brain MRI showed multiple acute ischemic infarcts in the left middle cerebral artery territory; cardiac imaging found a left ventricular mass suggestive of metastasis. She died one year later.
Neurology · Cureus · 14h
Jugular Venous Compression via Soft Cervical Collar in Shunt-Refractory Low-Pressure Hydrocephalus: A Report of Two Cases
Third ventricular width decreased from 13 to 8 mm in case 1 and 13 to 4 mm in case 2; ventriculomegaly recurred on collar cessation and resolved on reapplication in case 1
Neurology · Cureus · 17h
Neurosurgical Outcomes of Epilepsy Surgery Between 2017 and 2025: A Retrospective ESSQ-19 Study From a Tertiary Care Center
ESSQ-19 summary score was 84.1±21.7. Surgical complication domain scored 89.2±21.1 and seizure control 85.0±27.6, while psychosocial domain scored lower at 79.9±24.1.
Neurology · Cureus · 1d
Preservation of Non-nidal Medial Veins During Microsurgical Resection of Cerebral Arteriovenous Malformations: Technical Considerations and Early Clinical Outcomes
Complete angiographic nidus eradication in all 16 patients, no perioperative mortality, and mRS 0-2 in 14 patients (87.5%). No delayed venous infarction or haemorrhagic transformation occurred.
Neurology · Cureus · 1d
Thursday, 10 September 2026
Mass Effect Score Associations in Comatose Trauma Patients With Intracranial Hemorrhage Requiring Mechanical Ventilation: A Retrospective Study
Mortality and adverse outcomes were associated with MES ≥2 (both p 0.05). Failure to follow commands at three months was also associated with MES ≥2 (p 0.05).
Neurology · Cureus · 2d
When Speech Signals Wilson Disease: A Case Report
Kayser-Fleischer rings, reduced serum ceruloplasmin, elevated 24-hour urinary copper, decompensated liver disease, and MRI signal changes in basal ganglia, thalami, and periventricular white matter confirmed Wilson disease; D-penicillamine and zinc led to clinical improvement
Neurology · Cureus · 2d
Tumor-Related Trigeminal Neuralgia: Clinical Features, Pathophysiology, and the Contemporary Role of Radiosurgery in Tumor Control and Pain Relief
Microsurgery gave a higher proportion of favourable pain outcomes and, in one meta-analysis, longer median time to pain recurrence, with equivalent tumor control, mainly in petroclival and petrous apex meningioma.
Neurology · Cureus · 2d
Biohaven epilepsy drug suffers FDA hold days after attracting $350M deal
If you have patients on or awaiting BHV-7000 trials, recruitment is now paused pending rodent toxicity review, so discuss alternatives rather than enrolment timelines.
Neurology · Fierce Biotech · 2d
Loberamisal for Acute Ischemic Stroke: The LAIS Randomized Clinical Trial.
At 90 days, 69.7% on loberamisal reached mRS 0-1 versus 56.3% on placebo (risk difference 13.28%, 95% CI 7.24%-19.32%)
Neurology · JAMA · 2d
Wednesday, 9 September 2026
Surgical Deconstruction of Recurrent Basilar Apex Aneurysms Refractory to Endovascular Treatment
Both patients achieved safe, immediate and durable aneurysm disconnection; angiographic posterior communicating artery presence and an intraoperative perforator-free zone were key to the approach
Neurology · Cureus · 3d
Diagnostic Diplopia: Isolated Oculomotor Nerve Palsy With Normal Imaging
When imaging is normal in isolated oculomotor palsy, don't settle for microvascular cause—consider vasculitis, aneurysm, or infiltrative disease before discharging.
Neurology · Cureus · 3d
Oveporexton for Narcolepsy Type 1 - Results from Two Phase 3 Trials.
MWT sleep latency rose 14.3-19.8 minutes with oveporexton versus -0.4 to -0.8 with placebo; ESS fell 9.7-11.8 versus 1.5-1.7; cataplexy fell 79.0-88.8% versus 27.7-39.1% (all P<0.001).
Neurology · NEJM · 3d
Friday, 4 September 2026
Ionis’ ‘breakthrough’ Alexander disease approval establishes pillar of rare disease pipeline
First therapy for Alexander disease—an ASO targeting GFAP—offers a disease-modifying option for a fatal leukodystrophy, though availability in India remains unclear.
Neurology · Fierce Biotech · 8d
FDA Approves First Drug to Treat Alexander Disease
First-ever therapy for a fatal leukodystrophy; consider referral for pediatric or adult patients with confirmed GFAP mutation.
Neurology · FDA — Press Announcements · 9d
Thursday, 3 September 2026
Psilocybin proves promising in neuropathic pain mouse study
If confirmed in humans, psilocybin could offer a new option for chemotherapy-induced neuropathy, which often resists standard painkillers.
Neurology · Fierce Biotech · 9d
Natural history and clinical impact of epilepsy in adults with Down syndrome: a multicentre clinical study.
Cumulative incidence of epilepsy increased from 9.5% (95% CI 7.8-11.3) at Alzheimer's diagnosis to 56.9% (51.7-61.7) after 9 years. Epilepsy associated with increased mortality (HR 2.10 [95% CI 1.57-2.82]; p<0.0001) and faster cognitive decline.
Neurology · Lancet · 9d
Tuesday, 1 September 2026
Mechanical Thrombectomy in Ischemic Stroke With Medium or Distal Arterial Occlusion
For stroke patients with medium or distal occlusions, this trial clarifies whether adding thrombectomy to medical therapy improves outcomes—directly guiding your reperfusion decisions.
Neurology · JAMA · 11d
Mechanical Thrombectomy in Ischemic Stroke With a Medium or Distal Arterial Occlusion Research Summary
For stroke patients with medium or distal clots, this trial tests whether adding thrombectomy to standard care improves functional recovery—directly informing your reperfusion decisions.
Neurology · JAMA · 11d
One-Year Outcomes After Endovascular Treatment for Large Acute Ischemic Stroke
Confirms thrombectomy benefit persists at 1 year for large-core strokes, supporting its use in patients you might otherwise manage medically.
Neurology · JAMA · 11d
Page 1